Management of Vasomotor Symptoms in Cancer Patients

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2025 Mar 4

PMID 40037618

Authors

Ling Zhu

Tammy T Hshieh

Tara K Iyer

Alicia K Morgans

Ole-Petter R Hamnvik

Affiliations

Soon will be listed here.

Abstract

Many cancer treatments can lead to reduced levels of sex hormones, which in turn may cause vasomotor symptoms (VMS) such as hot flashes. These symptoms are associated with impaired quality of life, as well as suboptimal tolerability of and adherence to cancer treatment. Hormone therapy, performed by increasing estradiol or testosterone levels, is the gold standard for treatment of VMS. However, this approach is generally contraindicated in patients with hormone-sensitive cancers. Nonhormone agents with low to moderate efficacy in controlling VMS are available, but their use may be limited by side effects and tolerability. In this narrative review, the approach to VMS in cancer patients will be discussed. The evidence for various treatment options, including novel agents such as fezolinetant that target the hypothalamic thermoregulatory pathway, will be evaluated. Finally, special considerations in different patient populations based on cancer types (eg, breast, prostate) and age groups (eg, older adults) will be explored.

References

Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea D, Vlachos G . Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2015; 23(3):335-42. DOI: 10.1097/GME.0000000000000508. View

Beach S, Celano C, Sugrue A, Adams C, Ackerman M, Noseworthy P . QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2017; 59(2):105-122. DOI: 10.1016/j.psym.2017.10.009. View

Stuenkel C, Davis S, Gompel A, Lumsden M, Murad M, Pinkerton J . Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. DOI: 10.1210/jc.2015-2236. View

Lederman S, Ottery F, Cano A, Santoro N, Shapiro M, Stute P . Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023; 401(10382):1091-1102. DOI: 10.1016/S0140-6736(23)00085-5. View

Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist L, Wilking N . Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2012; 49(1):52-9. DOI: 10.1016/j.ejca.2012.07.003. View

Smith Jr J . Management of hot flushes due to endocrine therapy for prostate carcinoma. Oncology (Williston Park). 1996; 10(9):1319-22; discussion 1324. View

Crepeau-Gendron G, Brown H, Shorey C, Madan R, Szabuniewicz C, Koh S . Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. J Affect Disord. 2019; 250:341-345. DOI: 10.1016/j.jad.2019.02.060. View

Carpenter J . The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. 2001; 22(6):979-89. DOI: 10.1016/s0885-3924(01)00353-0. View

. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013; 121(4):887-890. DOI: 10.1097/01.AOG.0000428645.90795.d9. View

10.

Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G . Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022; 45(12):1539-1549. PMC: 9676852. DOI: 10.1007/s40264-022-01246-4. View

11.

Greene J . Constructing a standard climacteric scale. Maturitas. 1998; 29(1):25-31. DOI: 10.1016/s0378-5122(98)00025-5. View

12.

Barnard N, Kahleova H, Holtz D, Znayenko-Miller T, Sutton M, Holubkov R . A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial. Menopause. 2022; 30(1):80-87. PMC: 9812421. DOI: 10.1097/GME.0000000000002080. View

13.

Loprinzi C, Kugler J, Sloan J, Mailliard J, Lavasseur B, Barton D . Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2001; 356(9247):2059-63. DOI: 10.1016/S0140-6736(00)03403-6. View

14.

Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S . Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause. 2023; 31(1):68-76. PMC: 11812669. DOI: 10.1097/GME.0000000000002281. View

15.

Osborne C . Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339(22):1609-18. DOI: 10.1056/NEJM199811263392207. View

16.

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

17.

Rance N, Young 3rd W . Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology. 1991; 128(5):2239-47. DOI: 10.1210/endo-128-5-2239. View

18.

Tune L . Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001; 62 Suppl 21:11-4. View

19.

Engstrom C, Kasper C . Physiology and endocrinology of hot flashes in prostate cancer. Am J Mens Health. 2009; 1(1):8-17. DOI: 10.1177/1557988306294162. View

20.

Sloan J, Loprinzi C, Novotny P, Barton D, Lavasseur B, Windschitl H . Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001; 19(23):4280-90. DOI: 10.1200/JCO.2001.19.23.4280. View